OPC 21268

Known as: Acetamide, N-(3-(4-((4-(3,4-dihydro-2-oxo-1(2H)-quinolinyl)-1-piperidinyl)carbonyl)phenoxy)propyl)-, OPC-21268 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
1999
1999
OBJECTIVE Recent experimental evidence suggests that centrally released arginine vasopressin plays a significant role in brain… (More)
Is this relevant?
1999
1999
Arginine vasopressin (AVP) is known to contribute significantly to the pathogenesis of congestive heart failure and hypertension… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
Is this relevant?
Highly Cited
1998
Highly Cited
1998
The pharmacological profile and the acute and chronic aquaretic effects of OPC-41061, a novel nonpeptide human arginine… (More)
  • table 1
  • figure 2
  • figure 3
  • figure 4
  • table 2
Is this relevant?
1996
1996
The effects of the nonpeptide orally effective vasopressin V1 receptor antagonist OPC-21268 were studied in progressive focal… (More)
Is this relevant?
1994
1994
Rapid right ventricular pacing could induce congestive heart failure in conscious dogs with significant increase in plasma… (More)
Is this relevant?
1994
1994
We studied the hypotensive effects of OPC-21268, an orally effective nonpeptide vasopressin V1 receptor antagonist, in… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
1994
1994
In vascular smooth muscle cells arginine vasopressin acting through the V1 receptor increases intracellular Ca2+, leading to… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
1992
1992
An orally effective, nonpeptide vasopressin V1 receptor antagonist, OPC-21268 was produced for possible human use. We… (More)
  • figure 1
  • figure 2
  • table 1
  • figure 3
Is this relevant?
1992
1992
We investigated the effects of V1 IOPC-21268, 1-(1-[4-(3-acetylaminopropoxy)benzoyl]-4-piperidyl)-3,4-dihydro-2( 1H)- quinolinone… (More)
Is this relevant?
Highly Cited
1991
Highly Cited
1991
An orally effective, nonpeptide, vasopressin V1 receptor antagonist, OPC-21268, has been identified. This compound selectively… (More)
Is this relevant?